GSK to collaborate with Concert Pharmaceuticals on deuterium-modified drugs

GlaxoSmithKline has announced a collaboration worth up to $1 billion with Concert Pharmaceuticals of Lexington, Mass, involving the use of deuterium chemistry to create novel small molecule drugs.